Cytotoxic effector cells with antitumor activity can be amplified ex vivo from biopsies or blood of patients with renal cell carcinoma for cell therapy use

2003 ◽  
Vol 52 (11) ◽  
pp. 699-707 ◽  
Author(s):  
Françoise Bouet-Toussaint ◽  
Jean-Jacques Patard ◽  
Alban Gervais ◽  
Noëlle Genetet ◽  
Cécile Thomas de la Pintière ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Antitumor Activity ◽  
Cell Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Ex Vivo ◽  
Effector Cells ◽  
Cytotoxic Effector

scholarly journals Clinical Studies Applying Cytokine-Induced Killer Cells for the Treatment of Renal Cell Carcinoma

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Clara E. Jäkel ◽  
Stefan Hauser ◽  
Sebastian Rogenhofer ◽  
Stefan C. Müller ◽  
P. Brossart ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Antitumor Activity ◽  
Cell Therapy ◽  
Cell Carcinoma ◽  
Clinical Studies ◽  
Renal Cell ◽  
Standard Therapy ◽  
Mtor Inhibition ◽  
Cik Cells ◽  
Cik Cell

Metastatic renal cell carcinoma (RCC) seems to be resistant to conventional chemo- and radiotherapy and the general treatment regimen of cytokine therapy produces only modest responses while inducing severe side effects. Nowadays standard of care is the treatment with VEGF-inhibiting agents or mTOR inhibition; nevertheless, immunotherapy can induce complete remissions and long-term survival in selected patients. Among different adoptive lymphocyte therapies, cytokine-induced killer (CIK) cells have a particularly advantageous profile as these cells are easily available, have a high proliferative rate, and exhibit a high antitumor activity. Here, we reviewed clinical studies applying CIK cells, either alone or with standard therapies, for the treatment of RCC. The adverse events in all studies were mild, transient, and easily controllable.In vitrostudies revealed an increased antitumor activity of peripheral lymphocytes of participants after CIK cell treatment and CIK cell therapy was able to induce complete clinical responses in RCC patients. The combination of CIK cell therapy and standard therapy was superior to standard therapy alone. These studies suggest that CIK cell immunotherapy is a safe and competent treatment strategy for RCC patients and further studies should investigate different treatment combinations and schedules for optimal application of CIK cells.

V763 LAPAROSCOPIC-ASSIST RENAL INCISING AUTO-TRANSPLANT WITH EX-VIVO BENCH SURGERY FOR CENTRALLY LOCATED RENAL CELL CARCINOMA (LARIAT PROCEDURE)

2010 ◽  
Vol 183 (4S) ◽  
Author(s):  
Anthony Polcari ◽  
Ahmer Farooq ◽  
Cory Hugen ◽  
Peter Lundberg ◽  
Anthony LoGuidice ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Ex Vivo ◽  
Bench Surgery

scholarly journals T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy

2018 ◽  
Vol 6 (2) ◽  
pp. 222-235 ◽  
Author(s):  
Rikke Andersen ◽  
Marie Christine Wulff Westergaard ◽  
Julie Westerlin Kjeldsen ◽  
Anja Müller ◽  
Natasja Wulff Pedersen ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
T Cell ◽  
Cell Therapy ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Adoptive Cell Therapy ◽  
T Cell Responses ◽  
Cell Responses ◽  
Primary Renal Cell Carcinoma

Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model

2016 ◽  
Vol 12 (1) ◽  
pp. 69-79 ◽  
Author(s):  
Masatomo Nishikawa ◽  
Hideaki Miyake ◽  
Martin Gleave ◽  
Masato Fujisawa
Keyword(s):  
Renal Cell Carcinoma ◽  
Antitumor Activity ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Human Renal Cell Carcinoma
Sign in / Sign up

Export Citation Format

Share Document